Advanced NSCLC

169P_PR - Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)

Authors
  • E. Corral de la Fuente (Madrid, Spain)
  • A. Barquín García (Madrid, Spain)
  • C. Saavedra Serrano (Madrid, Spain)
  • M. Olmedo García (Madrid, Spain)
  • R. Martin Huertas (Madrid, Spain)
  • J. Serrano Domingo (Madrid, Spain)
  • V. Albarrán Artahona (Madrid, Spain)
  • A. Gómez Rueda (Madrid, Spain)
Speakers
  • E. Corral de la Fuente (Madrid, Spain)

Previous ePoster

No ePoster preview available
80P - High blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC)

Next ePosters
73P - Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries
31P - Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer
36P - Can a BALF profile distinguish hot vs cold lung tumors?
8P - Role of chemokines in resectable non-small cell lung cancer (NSCLC)
129P - Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer
22P - Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors
154P - Renal toxicity from platinum/pemetrexed and pembrolizumab in the era of combination therapy
47P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative
3P - Notable variation of molecular testing in metastatic lung cancer in the Netherlands
179P - Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) receiving atezolizumab (atezo) monotherapy in US clinical practice